ARS Pharmaceuticals files for approval of neffy in Canada, U.K.

TipRanks01-07 21:15

ARS Pharmaceuticals (SPRY) announced that ARS Pharma has filed for approval of neffy 2 mg in Canada and the United Kingdom, where it will be marketed as EURneffy, on behalf of its licensing partner, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2501202154?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-07 21:15","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2501202154","market":"us","top_or_hot":-1,"title":"ARS Pharmaceuticals files for approval of neffy in Canada, U.K.","media":"TipRanks","content":"<div>\n<p>ARS Pharmaceuticals (SPRY) announced that ARS Pharma has filed for approval of neffy 2 mg in Canada and the United Kingdom, where it will be marketed as EURneffy, on behalf of its licensing partner, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ars-pharmaceuticals-files-approval-neffy-131511272.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ARS Pharmaceuticals files for approval of neffy in Canada, U.K.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nARS Pharmaceuticals files for approval of neffy in Canada, U.K.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-07 21:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ars-pharmaceuticals-files-approval-neffy-131511272.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ARS Pharmaceuticals (SPRY) announced that ARS Pharma has filed for approval of neffy 2 mg in Canada and the United Kingdom, where it will be marketed as EURneffy, on behalf of its licensing partner, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ars-pharmaceuticals-files-approval-neffy-131511272.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SPRY","symbol_name":"ARS PHARMACEUTICALS INC","start_time":0,"source_url":"https://finance.yahoo.com/news/ars-pharmaceuticals-files-approval-neffy-131511272.html","article_id":"2501202154","we_media_id":null,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/ars-pharmaceuticals-files-approval-neffy-131511272.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2501202154","pubTimestamp":1736255711,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"ARS Pharmaceuticals  announced that ARS Pharma has filed for approval of neffy 2 mg in Canada and the United Kingdom, where it will be marketed as EURneffy, on behalf of its licensing partner, ALK- Abello A/S. neffy was recently approved in the U.S. for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh greater than or equal to30 kg. In November 2024, ARS Pharma announced a licensing agreement providing ALK with exclusive rights to commercialize neffy in Europe, Canada, United Kingdom and certain other geographies outside of the U.S.Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. ARS Pharmaceuticals adds neffy to Commercial national formularies. ARS Pharmaceuticals notes filings for neffy approval in China, Japan, Australia. ARS Pharmaceuticals files for approval of neffy in China, Japan and Australia","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SPRY":"ARS PHARMACEUTICALS INC","BK4139":"生物科技"},"translate_title":"ARS Pharmaceuticals在加拿大和英国申请批准neffy。","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPRY":0.9},"content_text":"ARS Pharmaceuticals (SPRY) announced that ARS Pharma has filed for approval of neffy 2 mg in Canada and the United Kingdom, where it will be marketed as EURneffy, on behalf of its licensing partner, ALK- Abello A/S. neffy was recently approved in the U.S. for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh greater than or equal to30 kg. In November 2024, ARS Pharma announced a licensing agreement providing ALK with exclusive rights to commercialize neffy in Europe, Canada, United Kingdom and certain other geographies outside of the U.S.\n\nStay Ahead of the Market:\n\nDiscover outperforming stocks and invest smarter with Top Smart Score Stocks\nFilter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener\n\n\n\nPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>\n\n\nSee Insiders’ Hot Stocks on TipRanks >> \n\n\nRead More on SPRY:\n\nARS Pharmaceuticals adds neffy to Commercial national formularies\nARS Pharmaceuticals notes filings for neffy approval in China, Japan, Australia\nARS Pharmaceuticals files for approval of neffy in China, Japan and Australia\nARS Pharmaceuticals announces planned launch of neffyinSchools\nARS Pharmaceuticals’ Strong Q3 2024 Highlights","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2501202154"}